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Abstract
Sialyltransferase activity has been determined in membrane preparations containing the Golgi apparatus that were isolated
from atherosclerotic and normal human aortic intima as well as in plasma of patients with documented atherosclerosis and
healthy donors by measuring the transfer of N-acetylneuraminic acid (NeuAc) from CMP-NeuAc to asialofetuin. The
asialofetuin sialyltransferase activity was found to be 2 times higher in the atherosclerotic intima as compared to the normal
intima and 2-fold higher in patients’ plasma than in that from healthy donors. The mean values of the apparent Michaelis
constant (Km) for the sialylating enzyme for both tissues did not differ and were close for the intima and plasma. In contrast,
the maximal velocity (Vmax) was 2 times higher for the atherosclerotic intima than for the normal intima and 3 times higher
for patients’ plasma than for that of the donors. These results suggest that the activity of asialofetuin sialyltransferases of
aortal intima is enhanced in atherosclerosis as is the secretion of their soluble forms into patients’ plasma. ß 2002 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Sialic acids are found at the terminal position of
mammalian cell surface sugar chains of glycoproteins
and glycolipids [1]. Tissue- and cell type-speci¢c ter-
minal glycosylation is important for cell recognition,
proliferation, adhesion, di¡erentiation and pheno-
type formation [2]. This is con¢rmed by the fact
that considerable changes in glycoconjugate compo-
sition and content occur during embryo- and carci-
nogenesis [3^5]. Termination of carbohydrate chain
synthesis signi¢cantly depends on activity, expression
and speci¢city of sialyltransferases. These enzymes
catalyze the transfer of N-acetylneuraminic acid
(NeuAc) residues to terminal non-reducing positions
of oligosaccharide chains of an acceptor glycoconju-
gate using CMP-NeuAc as the activated sugar donor
[6,7]. Sialyltransferases as well as other glycosyltrans-
ferases have an N-terminal cytoplasmic tail, a signal-
anchor domain, and an extended stem region which
is followed by the large COOH-terminal catalytic
domain oriented within the lumen of the Golgi ap-
paratus. Soluble forms of sialyltransferases can result
from the release of membrane-bound enzymes by
endogenous proteases, presumably by cleavage be-
0925-4439 / 02 / $ ^ see front matter ß 2002 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 0 1 ) 0 0 0 9 3 - X
* Corresponding author. Fax: +7-95-415-2962.
E-mail address: prokazova@cardio.ru (N.V. Prokazova).
BBADIS 62078 20-12-01
Biochimica et Biophysica Acta 1586 (2002) 123^128
www.bba-direct.com
tween the catalytic domain and the transmembrane
domain. Soluble sialyltransferases have been demon-
strated in serum and other body £uids, and increased
serum levels have been noted in disease states and
in£ammation [7].
At present there are several studies that demon-
strate in atherosclerosis increased levels and changes
in the composition of cell surface glycoconjugates,
such as gangliosides [8^10]. These ¢ndings allow to
suggest that expression of glycosyltransferases may
be one of the factors in regulating the synthesis of
cell type-speci¢c glycoconjugates of the involved tis-
sue in atherosclerosis.
In the present study we investigated sialyltransfer-
ase (ST) activity in uninvolved intima and athero-
sclerotic plaques of human aorta. We also compared
sialyltransferase activity in plasma of patients with
documented thickening of coronary arteries and oth-
er clinical manifestations of atherosclerosis with that
of subjects without these symptoms.
2. Materials and methods
The present investigation is in accordance with the
principles outlined in the Declaration of Helsinki
[11].
Cytidine 5P-monophospho[14C]acetylneuraminic
acid ammonium salt (speci¢c activity 351 or 287
mCi/mmol) was purchased from Amersham (UK);
cytidine 5P-monophospho-N-acetylneuraminic acid
sodium salt and asialofetuin were purchased from
Sigma (USA); sodium cacodylate was purchased
from Ferak (Germany).
2.1. Determination of ST activity in human blood
plasma
Blood was obtained from ¢ve donors without a
history of cardiovascular diseases (age 15^50 years)
and from six patients with atherosclerosis (age 35^64
years, angiographically documented thickenings in
coronary arteries). Plasma was prepared by 20 min
incubation of 10 ml blood with 1.76 ml anticoagulant
(2.5 g sodium citrate, 1.4 g citric acid, 100 ml water)
at room temperature with subsequent centrifugation
for 20 min at 3000Ug (4‡C). The resulting plasma
was re-centrifuged under the same conditions.
ST was assayed by the method described in [12,13],
with modi¢cations. Brie£y, 0.03 ml 0.1 M cacodylate
bu¡er (pH 6.8), 10 nmoles CMP[14C]NeuAc (total
activity 50 nCi), 0.03 ml plasma (1.6^2.0 mg protein),
and 0.5 mg asialofetuin in a total volume of 0.065 ml
were incubated for 1 h at 37‡C. The reaction was
stopped by the addition of 1% phosphotungstic
acid (PTA) and 5% trichloroacetic acid (TCA) on
ice and left in a refrigerator overnight. This pro-
longed incubation was necessary for better precipita-
tion of the labeled proteins and caused no more than
5% hydrolysis of NeuAc from fetuin. The precipitate
was ¢ltrated through GF/C ¢lters on 3 MM What-
man, presoaked in PTA^TCA mixture, and washed
with 10 ml of this mixture. An ethanol^ether mixture
(2:1) was used for the last washing. Radioactivity
was measured in a 1215 Rackbeta II scintillation
counter (LKB, Sweden). In every case the observed
activity was corrected for background transfer to en-
dogenous glycoproteins determined using identical
assays without added asialofetuin. The accuracy of
the method was þ 5%. The enzyme activity was cal-
culated as pmol NeuAc transferred to AF for 1 h by
1 mg plasma protein.
2.2. Determination of ST in human aortic intima
Aortas from 25^65-year-old men and women were
obtained aseptically within 12 h after their death due
to an accident, frozen in liquid nitrogen and stored
at 370‡C until use. At the day of the experiment the
tissues were defrosted, and further procedures were
carried out at 4‡C. The aortas were separated from
fat and connective tissue and cut lengthwise. The
occurrence and the type of atherosclerotic lesions
were de¢ned according to the classi¢cation proposed
by Smith [14]. Two types of aortas were de¢ned: the
¢rst had atherosclerotic lesions (presumably athero-
sclerotic plaques without necrosis, occupying about
half the total inner surface of the aortas) and the
second was without visible indications of lesions. In
every specimen, the intima was mechanically sepa-
rated from the media along the secondary internal
limiting membrane as described earlier [15]. Thus,
the intimas prepared from the ¢rst type of specimens
are further referred to as atherosclerotic intima and
those prepared from the second type as normal in-
tima. Two aortic specimens from di¡erent subjects
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were separated into an atherosclerotic plaque area
and its adjacent uninvolved area. The intimas iso-
lated from these areas were used for comparative
study on sialyltransferase activity.
The separated layer of the intima was blotted with
¢lter paper, weighed and cut into small pieces. The
intima pieces were frozen in liquid nitrogen and
ground to powder that was further suspended in
37.5 mM Tris-maleate bu¡er, pH 6.75, containing
0.25 M sucrose (1 g tissue in 20 ml bu¡er). The tissue
suspension was homogenized in Potter’s homogeniz-
er (glass-Te£on) and centrifuged at 1000Ug for 10
min. The resulting supernatant was centrifuged at
9000Ug for 20 min. After removing the pellet, the
supernatant was further centrifuged at 100 000Ug
for 1 h. The ¢nal membrane pellet, containing the
Golgi apparatus, was resuspended using a Potter’s
homogenizer in 0.1 M cacodylate bu¡er, pH 6.8,
containing 0.3% Triton X-100. The isolated mem-
brane fractions were stored at 370‡C.
ST activity was determined by the modi¢ed meth-
od of Senn et al. [16]. The membranes (0.16^0.20 mg
protein) in the cacodylate bu¡er were incubated with
50 nmoles CMP[14C]NeuAc (total activity 100 nCi)
and 0.5 mg asialofetuin in a total volume 0.2 ml for
1 h at 37‡C. ST activities in the atherosclerotic and
the uninvolved intima, isolated from the same aorta
specimen, were determined in a similar way with one
exception: the concentration of CMP[14C]NeuAc
was 2 times lower (0.025 mM) with the same total
activity (100 nCi). The reaction was stopped by ad-
dition of 1% PTA in 5% TCA on ice and left over-
night in a refrigerator. The precipitates were pro-
cessed as described for plasma. ST activity was
expressed as pmol NeuAc transferred to asialofetuin
for 1 h by 1 mg membrane protein.
2.3. Kinetic analysis
Plasma from two donors and two healthy volun-
teers as well as two atherosclerotic and two normal
intimal specimens were used in kinetic experiments.
The kinetic data for CMP-NeuAc were determined
using duplicate assays with saturating concentration
of asialofetuin (0.5 mg/assay) at 5^6 concentrations
of the donor substrate. Apparent Km and Vmax were
determined by the non-linear regression method
(RADLIG 4.0, Biosoft, UK).
2.4. Other analyses
Total NeuAc content was determined according to
[17]. Protein was measured by the modi¢ed method
of Peterson [18] using bovine serum albumin (Rean-
al, Hungary) for the calibration curve. Statistical
analysis was performed with InStat, version 1.12a
software (GraphPad, USA).
3. Results
ST activity was determined in blood plasma from
healthy donors (control plasma) and patients with
atherosclerosis (atherosclerotic plasma) as well as in
the membranes isolated from human intima of nor-
mal aortas (normal intima) and aortas with athero-
sclerotic lesions (atherosclerotic intima). These mem-
brane preparations containing the Golgi apparatus
were used for determination of aortic ST activity,
since it is well established that sialyltransferases are
located mainly in the Golgi apparatus [19]. The yield
of the membranes per g wet intima was 1.19 þ 0.05
and 1.65 þ 0.47 mg protein for the atheroscle-
rotic and normal intima, respectively. ST activity
was evaluated by the transfer of NeuAc from
CMP[14C]NeuAc to the glycoprotein, asialofetuin.
This glycoprotein acceptor was chosen because it
contains N- and O-glycoside linkages of the oligosac-
charide chains and can be sialylated into positions 3
and 6 of the terminal galactose [20]. The transfer of
CMP[14C]NeuAc to endogenous glycoproteins in
plasma and membranes was about 10^16% of that
in the presence of asialofetuin.
The total NeuAc content was similar in the athe-
rosclerotic and the normal intima and comprised
Table 1
ST activity (pmole NeuAc/h per mg membrane protein) in nor-
mal and atherosclerotic intima of human aorta
Specimen Normal intima Specimen Atherosclerotic intima
1 49.5 1 143.7
2 91.1 2 166.3
3 100.5 3 125.1
4 70,1 4 87.0
5 42.5 5 119.3
Mean þ S.D.: 70.7 þ 20.0 Mean þ S.D.: 128.1 þ 21.3*
*P6 0.005 vs. normal intima.
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0.205 þ 0.053 and 0.210 þ 0.046 mg per g wet tissue,
respectively. However, the mean ST activity was 2-
fold higher in the atherosclerotic intima than in the
normal intima (Table 1). ST activity, determined in
plasma of six atherosclerotic patients, was 2-fold
higher than that in plasma of ¢ve healthy subjects
(Table 2).
ST activity was linear with protein up to 0.3 mg/
assay for the membranes and up to 2 mg/assay for
the plasma. The incorporation of CMP[14C]NeuAc
in both tissues was dependent on asialofetuin and
reached a plateau at a concentration of 0.5 mg/assay.
Based on these data, in our typical experiments we
used 1.6^2.0 mg plasma protein or 0.16^0.20 mg
membrane protein and 0.5 mg asialofetuin. ST activ-
ity reached a maximum within 1 h and stayed con-
stant for at least 2 h (data are not shown).
Table 3 presents the values calculated from the
saturation curves. Fig. 1 shows typical saturation
curves for ST activities in the intima (A) and the
plasma (B). The Km values for NeuAc were the
same for the intima, atherosclerotic and normal,
and the plasma, atherosclerotic and normal. In con-
trast, the Vmax value for ST activity in the athero-
sclerotic intima was 1.8-fold higher than that in the
normal intima. In the atherosclerotic plasma Vmax
for ST was 3-fold higher than in normal plasma
(Table 3).
Table 2
ST activity (pmole NeuAc/h per mg plasma protein) in plasma
from healthy donors and atherosclerotic patients
Specimen Donor Specimen Patient
1 59.5 1 84.7
2 35.3 2 81.9
3 61.5 3 145.4
4 62.6 4 102.8
5 34.4 5 91.1
6 102.0
Mean þ S.D.: 50.7 þ 12.6 Mean þ S.D.: 101.3 þ 15.6*
*P6 0.005 vs. donor group.
Table 3
The kinetic properties of ST activity in aortic intima and blood plasma (for CMP-NeuAc)
Aortic intima Blood plasma
Atherosclerotic Normal Atherosclerotic Normal
Km 56.3 þ 11.3 56.6 þ 13.5 70.0 þ 5.3 60.1 þ 7.3
Vmax 319 þ 65.0 164 þ 10.5 357 þ 21.9 120 þ 8.7
Kinetic constants were determined under the assay conditions described in Section 2 with varying concentrations of CMP-NeuAc
(0.002^0.2 mM) and saturating concentration of asialofetuin. Km and Vmax values were obtained by the method of non-linear regres-
sion (program RADLIG 4.0). Km is expressed as WM, Vmax is expressed as pmol/h per mg membrane protein for aortic intima or mg
plasma protein for blood plasma. The values are means þ S.D. from two di¡erent tissue specimens.
Fig. 1. The relationship between ST activity and concentration
of CMP-NeuAc for intima (A) and plasma (B). The membranes
(0.2 mg protein) or blood plasma (2.0 mg protein) and asialofe-
tuin (0.5 mg) were incubated with varying concentrations of
CMP-NeuAc (0.002^0.2 mM) for 1 h at 37‡C. One of three
typical experiments is demonstrated. The values are the means
of two parallel measurements with error þ 5%.
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Table 4 shows that the ST activities in intimas
from the atherosclerotic lesion and its adjacent unin-
volved area, which were isolated from the same aorta
fragment, have similar values. It is necessary to note
that the latter experiments were carried out using a
2-fold less amount of CMP[14C]NeuAc than in the
experiments presented in Table 1. Due to this, the
levels of asialofetuin sialylation in these two groups
of experiments are di¡erent.
4. Discussion
The results of the present investigation show that
the membrane preparations containing the Golgi ap-
paratus, isolated from human aortic intima, were
able to sialylate asialofetuin in the presence of
CMP-NeuAc. The intima from normal una¡ected
aortas and aortas with atherosclerotic lesions, iso-
lated from several subjects, showed di¡erent asialo-
fetuin-sialylating activity. The Vmax values for the
atherosclerotic intima were higher than that for the
normal intima. However, the calculated Km values
were similar for the atherosclerotic and normal inti-
mas. Thus, the kinetic studies suggest that the higher
ST activity in the atherosclerotic intima may be re-
lated to a higher expression of the same enzyme or
the same group of enzymes.
The experiments on ST activity in the atheroscle-
rotic area and its adjacent uninvolved area of the
same aorta revealed similar values. Thus, the pres-
ence of atherosclerotic lesions appears to in£uence
NeuAc metabolism in the aorta as a whole.
The increased ST activity in the atherosclerotic
intima correlates well with the increased ST activity
in plasma from patients with documented atheroscle-
rosis. Blood plasma is known to contain soluble
forms of glycosyltransferases that are secreted by
the cells after the proteolysis of Golgi membrane-
bound enzymes [7]. Therefore, a relationship between
the increase in ST activity in the atherosclerotic in-
tima and the increase in ST activity in the patients’
plasma cannot be ruled out.
A similar observation was made recently during
cancerogenesis. Glycosyltransferases, speci¢c for tu-
mor cells, were found in blood from patients with
neoplastic diseases while glycosyltransferases of liver
origin are found in the blood from healthy subjects
and experimental animals [21^23].
The increase in ST activity may be related to
pathological processes, taking place during athero-
sclerotic plaque formation. It is known that intimal
smooth muscle cells change their phenotype from
contractile to synthetic with increasing synthesis
and secretion of extracellular matrix proteins [24].
Increased ST levels were observed recently at a sim-
ilar dedi¡erentiation of some cells [25^29].
As we have shown, while the total NeuAc content
was similar in the atherosclerotic and normal inti-
mas, the ST activity was higher in the atherosclerotic
intima. Similar discrepancies were observed recently
for ST activity and the level of sialylated proteins
during in£ammation, being explained by activation
of sialidase [30]. As atherosclerotic lesions resemble
in£ammatory focus [31], the activation of catabolic
enzymes, in particular sialidase, is not excluded.
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